Stocklytics Platform
Asset logo for symbol EXEL
Exelixis
EXEL74
$22.46arrow_drop_down0.61%-$0.14
High Quality
Asset logo for symbol EXEL
EXEL74

$22.46

arrow_drop_down0.61%
Key Stats
Open$22.65
Prev. Close$22.60
EPS0.65
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
LOWHIGH
Day Range22.44
22.75
52 Week Range18.64
24.34
Ratios
EPS0.65
Fundamentals
Payout Ratio-
Industry average yield2.85%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell
Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

EXELarrow_drop_up0.18%
US Healthcare Sectorarrow_drop_up0.50%
US Marketarrow_drop_down1.27%
check_circle
EXEL / Market
EXEL exceeded the US Market which returned -1.27% over the last twenty four hours.
warning
EXEL / Healthcare Sector
EXEL lose to the US Healthcare sector which returned 0.50% over the last twenty four hours.

Exelixis (EXEL) Statistics

Exelixis Inc (EXEL) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of cancer. The company's primary product is CABOMETYX, an oral multi-kinase inhibitor that targets the tumor microenvironment and inhibits the growth and spread of cancer cells. With a market capitalization of over $7 billion, Exelixis Inc has established itself as a key player in the biotech industry.

When it comes to valuation metrics, Exelixis Inc boasts impressive numbers. The company has a price-to-earnings ratio of 26.34, indicating that investors are willing to pay a premium for its earnings growth potential. Additionally, Exelixis Inc has a price-to-sales ratio of 9.22, highlighting its strong revenue generation capabilities. These valuation metrics suggest that the market has high expectations for the company's future performance.

add Exelixis  to watchlist

Keep an eye on Exelixis

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
How has Exelixis (EXEL) stock's performance compared to its sector and the market over the past year?

Over the past year, Exelixis (EXEL) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 23.68%, Exelixis has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 50.98%, it has fallen short of the market average. This comparison highlights Exelixis 's performance relative to both its sector and the overall market over the last year.

help
What is the PE ratio of Exelixis (EXEL) stock?

The PE (Price to Earnings) ratio of Exelixis (EXEL) is currently 34.55. This metric is used to evaluate the valuation of a company's stock, comparing its current share price relative to its per-share earnings.

help
What is the EPS of Exelixis (EXEL) stock?

The Earnings Per Share (EPS) for Exelixis (EXEL), calculated on a diluted basis, is $0.65. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.

help
What is the operating margin of Exelixis (EXEL) stock?

The operating margin for Exelixis (EXEL) is 14.65%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.

help
What is the EBITDA of Exelixis (EXEL) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Exelixis (EXEL) is $196.6M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.

help
How much debt does Exelixis (EXEL) have?

Exelixis (EXEL) has a total debt of $201.47M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$58.1M.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level